Histone Deacetylase Inhibitors in Pediatric Brain Cancers: Biological Activities and Therapeutic Potential

Alexandre Perla1,2, Lívia Fratini1,2, Paula S. Cardoso1,2, Carolina Nör3,4, André T. Brunetto1,5, Algemir L. Brunetto1,5, Caroline Brunetto de Farias1,5, Mariane Jaeger1,5 and Rafael Roesler1,2*

1 Cancer and Neurobiology Laboratory, Experimental Research Center, Clinical Hospital (CPE-HCPA), Federal University of Rio Grande do Sul, Porto Alegre, Brazil, 2 Department of Pharmacology, Institute for Basic Health Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Brazil, 3 The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON, Canada, 4 Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON, Canada, 5 Children’s Cancer Institute, Porto Alegre, Brazil

Brain cancers are the leading cause of cancer-related deaths in children. Biological changes in these tumors likely include epigenetic deregulation during embryonal development of the nervous system. Histone acetylation is one of the most widely investigated epigenetic processes, and histone deacetylase inhibitors (HDACis) are increasingly important candidate treatments in many cancer types. Here, we review advances in our understanding of how HDACis display antitumor effects in experimental models of specific pediatric brain tumor types, i.e., medulloblastoma (MB), ependymoma (EPN), pediatric high-grade gliomas (HGGs), and rhabdoid and atypical teratoid/rhabdoid tumors (ATRTs). We also discuss clinical perspectives for the use of HDACis in the treatment of pediatric brain tumors.

Keywords: medulloblastoma, ependymoma, glioma, histone deacetylase inhibitors, epigenetics, brain tumor

INTRODUCTION

Brain tumors of the childhood represent the leading cause of cancer-related deaths in children aged 0–14 years, and survivors often present long-term neurological sequelae that impair their quality of life (Ostrom et al., 2016). These cancer types include medulloblastoma (MB), which is the most common and most studied type of childhood brain tumor, ependymoma (EPN), pediatric high-grade gliomas (HGGs), and rhabdoid and atypical teratoid/rhabdoid tumors (ATRTs) (Guerreiro Stucklin et al., 2018). Pediatric brain cancers may originate from defects in embryonal development affecting cell types including neural stem cells (NSCs) and neuronal precursors, or dedifferentiation of mature neuronal or glial cells (Taylor et al., 2005; Visvader, 2011; Liu and Zong, 2012; Wang and Wechsler-Reya, 2014; Azzarelli et al., 2018).

Normal development, cellular differentiation, and tissue specialization are finely regulated by various epigenetic mechanisms (Atsisi and Stunnenberg, 2017). Epigenetic regulation allows changes in chromatin structure that control gene expression without modifications in DNA sequence. Histone acetylation and DNA methylation feature among the most widely investigated epigenetic mechanisms (Surani et al., 2007). Histone acetyltransferases (HATs) and deacetylases (HDACs) play opposing roles in regulating gene expression. HATs transfer acetyl groups to the amino-terminal lysine residues of histones, thus increasing histone acetylation and transcriptional activity. On the other hand, HDACs remove acetyl groups, thus promoting chromatin condensation and overall repression of gene expression, in addition to displaying other, non-epigenetic actions (Kouzarides, 2007; Sanai and Kavosoi, 2019; D’Mello, 2020; Milazzo et al., 2020). Changes in
the expression and activity of HATs and HDACs were described in leukemias, and afterward in solid tumors, and in many cases decreased levels of histone acetylation were shown to correlate with clinical outcome. Therefore, HDAC inhibitors (HDACis) have become promising and widely investigated experimental anticancer agents (Lane and Chabner, 2009; Li and Seto, 2016).

Pediatric cancers hijack and modify biological processes involved in normal embryonic development, including epigenetic modifications, to promote tumor progression (Liu and Zong, 2012; Marshall et al., 2014). An important component of childhood cancer biology is epigenetic reprogramming that can lock cells in a stem cell-like, poorly differentiated and highly proliferative phenotype (Lawlor and Thiele, 2012). Accumulating evidence implicates epigenetic abnormalities in the genesis and progression of pediatric brain tumors. The relationship between epigenetic markers and patient survival has been investigated (Bhattacharya et al., 2020), and epigenetic modulators have shown promising effects in experimental models. Here we review the potential of HDACis in the treatment of selected types of brain cancer that afflict children.

### EPGENETIC BASIS OF PEDIATRIC BRAIN CANCERS

Mutations and genetic variations affecting epigenetic-regulating mechanisms are features of several types of childhood brain cancers, including MB, EPN, ATRT, and pediatric gliomas (Mack and Taylor, 2009; Parsons et al., 2011; Dubuc et al., 2012; Jones et al., 2012; Lee et al., 2012; Northcott et al., 2012; Buczkowicz et al., 2014; Mack et al., 2016). In fact, MB and low-grade gliomas are among the types of pediatric tumors with highest frequency of mutation in genes encoding epigenetic regulators (Huether et al., 2014). MicroRNAs (miRNAs) regulate pediatric brain tumor cells at posttranscriptional/translational levels, acting on a range of functional aspects linked to cancer progression, including proliferation and stemness. The diagnostic, prognostic, and therapeutic potential of miRNAs has been increasingly highlighted (Garg et al., 2015; Leichter et al., 2017; Pezuk et al., 2019). Epigenetic remodeling genes SMARCb1 and SMARCA4 are among the most frequently altered in pediatric brain tumors, with most cases of ATRT showing changes in those genes (Frühwald et al., 2016; Wang et al., 2017; Johann, 2020). Enhancer of zeste homolog 2 (EZH2), which is part of a Polycomb repressor complex that methylates lysine 27 of histone H3 (H3K27), leading to transcription inhibition, is often mutated or highly expressed in pediatric brain tumors (Huether et al., 2014; Li et al., 2015; Kim and Roberts, 2016; Erkek et al., 2019; Zhang et al., 2020).

A reduced histone acetylation state can contribute to cancer through repressing differentiation and tumor suppressor genes while allowing overexpression of genes promoting proliferation. Chromatin modifications mediated by histone acetylation can also epigenetically influence the tumor genetic landscape, for example by leading to DNA copy gain in the absence of chromosomal instability (Black et al., 2013; Mack et al., 2016). HDACs play a central role in epigenetic regulation through reducing acetylation. It is currently known that some HDACs can either repress or activate gene transcription, in addition to displaying non-epigenetic activities by acting directly on nuclear and cytoplasmic proteins (D’Mello, 2020). For example, transcription factors E2F1, STAT1, STAT3, and NF-κB can be directly hyperacetylated by HDACis (Johnstone and Licht, 2003; Glozak et al., 2005; Bolden et al., 2006).

Histone acetyltransferases and deacetylases are currently classified into different classes. Class I HDACs include nuclear HDAC1, 2, 3, and 8. Class II HDACs occur in both the nucleus and cytoplasm and are classified into two subclasses: HDAC4, 5, 7, and 9 are grouped as Iia, whereas HDAC6 and 10 are classified as class Ib. Sirtuins constitute Class III HDACs, being found in the nucleus, cytoplasm, and mitochondria according to the specific type. Finally, HDAC11 has been proposed as a Class IV HDAC (Falkenberg and Johnstone, 2014; Hassell, 2019; D’Mello, 2020; Milazzo et al., 2020). Most deacetylase activity in mammalian cells has been attributed to Class I HDACs (Lahm et al., 2007).

Increased HDAC2 expression (Park et al., 2003), deletions or amplifications of histone methyltransferases and demethylases (Northcott et al., 2009), DNA hypermethylation (Frühwald et al., 2001), and altered miRNA expression (Ferretti et al., 2008) have been reported in MB. High HDAC5 and HDAC9 expression is found in prognostically poor MB subgroups and significantly associated with poor overall survival, posing an independent risk factor (Milde et al., 2010). Other alterations in epigenetic components found in MB include truncating mutations in the KDM6A gene encoding a histone 3 lysine 27 demethylase (Jones et al., 2012), homozygous deletions of genes involved in histone lysine methylation, and amplification of the HAT gene MYST3 (Northcott et al., 2009). Expression of HDAC2 is higher in patients with MB subgroups with poor prognosis (sonic hedgehog (SHH), Group 3 and Group 4), and MYC-amplified MB cell lines show increased mRNA levels of class I HDACs compared to the normal cerebellum (Ecker et al., 2015).

Hypermethylation of the transcriptional repressor hypermethylated in cancer 1 (HIC-1) was identified in 83% of EPN samples (Waha et al., 2004). Global reduction of H3K27me3 analogous to H3K27M mutant gliomas, accompanied by CpG hypermethylation, is found in EPN (Bayliss et al., 2016). Poor-prognosis EPNs show a CpG island methylator phenotype, where transcriptional silencing driven by CpG methylation converges on targets of the Polycomb repressive complex 2 (PRC2), which expresses repression of differentiation genes through trimethylation of H3K27 (Mack et al., 2014). Posterior fossa type A (PFA) EPNs show low H3K27 methylation and high levels of Enhancer of Zeste Homologs Inhibitory Protein (EZHIP), which promotes a similar chromatin state compared to H3K27M (Jain et al., 2019). Enrichment of 5-carboxylcytosine (5caC) and increased TET1 expression, which are involved in active DNA demethylation, are epigenetic hallmarks of EPN and SHH MB (Ramsawhook et al., 2017). Hypermethylated genes in EPN converge on defined sets of embryonic stem cell (ESC) targets, suggesting a linkage, mediated by epigenetic programming, between embryonic development and pediatric brain cancer (Sin-Chan and Huang, 2014; Mack et al., 2016).
Somatic mutations in the H3.3-ATRX-DAXX chromatin remodeling pathway and recurrent mutations in the gene encoding the histone 3 variant H3.3 are highly prevalent in pediatric glioblastoma (Schwartzentzuber et al., 2012). In diffuse intrinsic pontine glioma (DIPG), a deadly type of childhood glioblastoma, a mutation that leads to hypomethylation by replacing a lysine to methionine (K27M) on H3F3A and HIST1H3B/C genes encoding histone variants is the most frequent mutation (Wu et al., 2012, 2014; Mendez et al., 2020). Supporting the link between embryonic development and the arising of pediatric brain tumors, this histone mutation can contribute to resetting neural progenitors derived from human ESCs to a stem cell state, ultimately resulting in neoplastic transformation (Funato et al., 2014).

In ATRTs, HDAC1 is significantly differentially expressed (Sredni et al., 2013), and the chromatin remodeling and tumor suppressor gene SMARC1 represses Cyclin D1 transcription by recruiting the HDAC1 complex to its promoter, resulting in cell cycle arrest (Tsikitis et al., 2005). A hallmark of malignant rhabdoid tumors is homozygous deletion or inactivation of SMARC1. Histone acetylation and methylation patterns, as well as HDAC and HAT levels, are influenced by insulin-like growth factor receptor 1 (IGF-1R) signaling (Shim et al., 2013). For comprehensive reviews on the role of epigenetic changes as part of the biological basis of pediatric brain cancers, see Dubuc et al. (2012) and Mack et al. (2016).

**EFFECTS OF HDAC INHIBITION IN EXPERIMENTAL PEDIATRIC BRAIN CANCERS**

Most HDACiS widely used experimentally or clinically preferentially inhibit Class I and II HDACiS. These agents include sodium butyrate (NaB), trichostatin A (TSA), valproic acid (VPA), suberoyl anide hydroxamic acid (SAHA, vorinostat), panobinostat, belinostat, and romidepsin (Bolden et al., 2006; Li and Seto, 2016; Millard et al., 2017; Hassell, 2019). HDACiS induce anticancer effects in several experimental tumor types by targeting aberrant chromatin alterations, resulting in changes in cell proliferation, viability, differentiation, migration, and angiogenesis (Bolden et al., 2006; Sanaei and Kavoussi, 2019; Ribatti and Tamma, 2020). In addition to modulating acetylation by inhibiting HDACiS, HDACiS may directly modulate miRNAs and also alter protein kinase signaling through acetylation-independent mechanisms (Chen et al., 2005; Autin et al., 2019). The HDACi TSA inhibits HDAC6, a predominantly cytoplasmic HDAC, which likely induces many effects independent of alterations in gene expression stimulated by histone acetylation (Johnstone and Licht, 2003; Chen et al., 2005; Glozak et al., 2005). When combined with agents targeting other epigenetic regulators, such as EZH2, HDACiS modulate acetylation and methylation of H3K27, through mechanisms involving PRC2 complex disruption (Lue et al., 2019). Below, we summarize studies examining the effects of HDACiS in experimental models of pediatric brain tumors.

**Medulloblastoma**

Medulloblastoma is currently classified within four distinct molecular subgroups, namely, WNT, SHH, Group 3, and Group 4, with subtypes within each group being now recognized (Louis et al., 2016). An early study by Jaboin et al. (2002) showed that the HDACi MS-275 inhibits proliferation of Daoy and D283 Med MB cells. A subsequent study by Li and colleagues showed that VPA, which partially acts as a Class I and II HDACi, when used at clinically safe concentrations, leads to growth inhibition, cell cycle arrest, apoptosis, senescence, differentiation, and inhibition of colony formation in Daoy and D283 Med cells. In addition, daily systemic injection of VPA (400 mg/kg) for 28 days significantly inhibits in vivo growth of Daoy and D283 Med xenografts in immunodeficient mice. These effects are associated with hyperacetylation of histone H3 and H4, activation of p21, and suppression of TP53, CDK4, and c-MYC (Li et al., 2005). The HDACiS SAHA, NaB, and TSA induce apoptotic cell death related to dissipation of mitochondrial membrane potential and activation of caspase-9 and -3 in Daoy and UW228-2 MB cells. These HDACiS also enhance the cytotoxic effects of ionizing radiation in Daoy cells, and treatment with SAHA potentiates the cytotoxic actions of etoposide and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), but not vincristine (Sonnenmann et al., 2006). HDACi-induced TRAIL sensitization is associated with increased caspase-8 activation (Sonnenmann et al., 2012). VPA combined with interferon (IFN)-gamma restores caspase-8 expression and sensitivity to TRAIL in primary MB samples and significantly potentiates TRAIL-mediated suppression of MB growth in vivo (Häcker et al., 2009). HDACi potentiation of ionizing radiation effects in MB cells was also reported by Kumar et al. (2007). A variety of HDACiS, including MS-275, SAHA, TSA, and VPA, are able to inhibit proliferation of MB cell lines and induce histone H4 hyperacetylation, reactivation of expression of growth regulatory genes, and induction of apoptosis, as well as reduction of MB xenograft growth in vivo (Furchert et al., 2007). HDACiS helminthosporium carbonum (HC)-toxin, SAHA, and panobinostat reduce viability and lead to radiosensitization accompanied by increased cell death in the HD-MB03 cell line, a preclinical model of Group 3 MB (Milde et al., 2012). Inhibition of class I HDACiS in MB cells reduces metabolic activity, cell number, and viability and enhances sensitivity to HDACi specifically in MYC-amplified cells (Ecker et al., 2015). Histone-mediated deregulation of expression of the Wnt antagonist Dickkopf-1 (DKK1) impairs its tumor-suppressing activity and contributes to experimental MB tumorigenesis, and treatment with TSA restores DKK1 in D283 Med cells (Vibhakar et al., 2007). TSA significantly inhibits telomerase activity, increases expression of p53 and p21, and reduces cyclin-D levels in ONS-76 MB cells. Upregulation of Bax and cytochrome c correlates with pro-apoptotic effects in TSA-treated cells (Khaw et al., 2007). HDACi-mediated deacetylation of Gli (glioma-associated oncogene) promotes transcriptional activation through Hedgehog (Hh)-induced upregulation of HDACi, and loss of HDAC activity hinders Hh pathway-dependent growth of neural progenitors and MB cells (Canettieri et al., 2010; De Smaele et al., 2011). The functional interaction between the transcription
cofactor ZNF521 and GLI1 and GLI2, which enhances Hh signaling, is sensitive to HDACis (Scicchitano et al., 2019). Hh signaling stimulates granule precursor (CGP) proliferation during the early stages of postnatal cerebellar development and sustains HDAC activation leading to stimulation of CGPs. HDAC inhibition impairs Shh-induced CGP proliferation and improves aberrant CGP proliferation in a mouse model of MB (Lee et al., 2013). NL-103, a dual-targeted inhibitor of both HDAC and Hh signaling, effectively overcame resistance to the Hh inhibitor vismodegib (Zhao et al., 2014). HDAC6 is an important regulator of the Hh pathway, and selective HDAC6 inhibition hinders MB cell survival in vitro and reduces tumor growth in an in vivo allograft model (Dhanyamraju et al., 2015). HDACis show more pronounced effects on proliferation of SHH-driven MB cells harboring a mutation in the gene encoding for the histone acetyltransferase (HAT) CREBBP, when compared to CREBBP wild-type controls (Hellwig et al., 2019). A targeted small-molecule screen on the stable, SHH-dependent murine MB cell line SMB21 reveals selective inhibitors of class I HDACs as promising antitumor agents for SHH MB, and the novel class I HDAC inhibitor JNJ-26481585 (quisinostat) consistently inhibits growth of SHH MB in vivo as well as in vitro (Pak et al., 2019). Another recent study using a high-throughput cell viability assay to screen 12,800 compounds identified two HDACis, JNJ-26481585 and dacinostat, as anti-proliferative agents in MB. Both compounds induce cytotoxicity and apoptosis and block cell cycle progression at the G2/M phase, in addition to reducing the growth of MB xenografts in mice (Zhang et al., 2019).

Histone deacetylase inhibitors sensitize MB cells to apoptosis induced by cytotoxic chemotherapy via an enhancement of p53-dependent Bax activation (Häcker et al., 2011). The HDACi sodium butyrate (NaB) at a low dose more effectively inhibits D283 cell viability when combined with the chemotherapeutic etoposide (Nör et al., 2013). SAHA combined with 13-cis retinoic acid (RA) induces apoptosis and transcription of bone morphogenetic protein-2 (BMP-2) in MB cells and is more effective than each drug alone in inhibiting MB growth in vitro and in vivo. Moreover, intracranial MB tumors in mice treated with SAHA plus RA plus cisplatin show a 4-fold increase in apoptosis over controls, and a 2-fold increase over animals receiving only SAHA or RA plus SAHA (Spiller et al., 2008). The combination of RA with epigenetic modulators in based upon functional interplays among retinoid receptors, histone acetylation, and DNA methylation. For example, HDACs bind to RA response elements in proximal promoters or enhancer regions of genes regulated by retinoids in stem cells, and retinoid receptors interact with the transcription complex mediating the placement or removal of epigenetic marks on histones and DNA (Gudas, 2013; Urvalek and Gudas, 2014; Almeida et al., 2017). Combinations of HDACis with other epigenetic modulators have also been evaluated. SAHA plus the DNA methyltransferase 1 (DNMT) inhibitor 5-aza-2′-deoxycytidine (5-aza-dC) produce a synergistic effect on survival of Daoy and D283 Med MB cells (Yuan et al., 2017).

Combining HDACis with growth factor receptor ligands such as receptor tyrosine kinase (RTK) inhibitors (gefitinib or vandetanib) or brain-derived neurotrophic factor (BDNF) is also more effective than each agent given alone in impairing MB cell viability (Marino et al., 2011; Nör et al., 2011). However, bombesin receptor antagonists failed to potentiate the effects of HDACi inhibition (Jaeger et al., 2016). Other studies have investigated combinations of HDACis with protein kinase signaling inhibitors. The multi-kinase inhibitor sorafenib and VPA interact to radiosensitize and kill MB cell lines (Tang et al., 2012). SAHA shows additive cytotoxicity with the Aurora A kinase inhibitor MLN8237 in Daoy cells (Muscal et al., 2013a). A study by Geron et al. (2015) examined the effects of the pan-aurora kinase inhibitor AMG 900 alone or in combination with SAHA in UW402, UW473, and ONS-76 MB cells. A synergistic effect of combining AMG 900 and SAHA is observed on cell proliferation in all these cell lines, especially in sequential drug treatment. The drug combination also fully inhibits cell survival measured by colony formation. Using an animal model of MYC-driven MB to screen for promising drugs, Pei et al. (2016) found HDACis among the most effective compounds. HDACis potently inhibit survival of MYC-driven MB cells, through a mechanism involving expression of the FOXO1 tumor suppressor gene. Importantly, HDACis synergize with phosphatidylinositol 3-kinase (PI3K) inhibitors to inhibit MB growth in vivo. NaB reduces viability and increases acetylation in human MB cells, the anti-proliferative effect of NaB being enhanced by combination with a mitogen-activated protein kinase (MAPK)/extracellular-related kinase (ERK) inhibitor (Jaeger et al., 2020).

**Ependymoma**

Ependymomas featuring a CpG island methylator phenotype respond to drugs that target DNA or H3K27 methylation, revealing epigenetic modulators as the first rational therapeutic candidates in this tumor type (Mack et al., 2014). In a high-risk cytogenetic group 3 and molecular group C EPN model (DKFZ-EP1NS) that shows high tumorigenic potential in vivo, cells are resistant to cytotoxic chemotherapeutics temozolomide, vincristine, and cisplatin but respond to HDACi treatment (Milde et al., 2011).

**Diffuse Intrinsic Pontine Glioma**

A seminal study using a chemical screen in patient-derived DIPG cultures along with RNA-seq analyses and integrated computational modeling to identify potentially effective therapeutic strategies has highlighted the potential of HDACs as targets. Importantly, the HDACi panobinostat showed antitumor efficacy both in vitro and in orthotopic xenograft models. Furthermore, combination of panobinostat with the histone demethylase inhibitor GSK-J4 showed that the two had synergistic effects (Grasso et al., 2015). Another study of panobinostat in experimental DIPG found that it effectively impaired cell proliferation, viability, and clonogenicity and induced apoptosis in human and murine DIPG cells. In genetically engineered tumor-bearing mice, panobinostat reduced tumor growth and increased H3 acetylation. Extended daily treatment of both genetic and orthotopic xenograft models with 10 or 20 mg/kg panobinostat led to significant toxicity, while reduced, well-tolerated doses of panobinostat failed to prolong overall survival (Hennika et al., 2017). In DIPG primary
cells, panobinostat potentiated the effects of gene therapy based on human adipose tissue-derived mesenchymal stem cells expressing the secreted form of TRAIL (hAT-MSCs-TRAIL), inducing a decrease in tumor volume and prolonging survival (Choi et al., 2019).

Combined treatment with the HDACi panobinostat and the AXL inhibitor BGB324 resulted in synergistic antitumor effects on DIPG cells, with reduced expression of genes related to mesenchymal phenotype, stemness, and DNA damage repair (Meel et al., 2020). HDACis also synergize with blockade of bromodomain inhibition or CDK7, which disrupts oncogenic transcription, in DIPG models. HDAC inhibition by panobinostat, together with the bromodomain inhibitor JQ1 or the CDK7 inhibitor THZ1, synergistically reduced cell viability in DIPG cell cultures and proved more effective than single-drug treatments in inhibiting proliferation and inducing apoptosis. Panobinostat and JQ1 induced overlapping transcriptional changes, downregulating many of the same sets of genes (Nagaraja et al., 2017). VPA potentiates carboxatin cytotoxicity and increases histone H3 acetylation in different DIPG cell lines (Killick-Cole et al., 2017). CUDC-907, a first-in-class dual inhibitor of HDACs and PI3K, is a potent cytotoxic agent in DIPG models. Mechanisms underlying CUDC-907 actions include regulation of DNA damage response. It also displays radiosensitizing effects mediated by decreased nuclear factor kappa B (NFκB/Forkhead box M1 (FOXM1)) recruitment to promoters of genes involved in response to DNA damage (Pal et al., 2018). A CRISPR screen showed that knockout of KDM1A encoding lysine-specific demethylase 1 (LSD1) sensitizes DIPG cells to HDACis. Corin, an HDAC and LSD1 inhibitor, hinders in vitro and in vivo DIPG growth by increasing H3K27me3 levels as well as HDAC-targeted H3K27ac and LSD1-targeted H3K4me1 at differentiation-associated genes (Anastas et al., 2019).

Rhabdoid and Atypical Teratoid/Rhabdoid Tumors

Atypical teratoid/rhabdoid tumors cell proliferation is impaired by a variety of HDACis, including MS-275, SAHA, TSA, and VPA (Jaboin et al., 2002; Furchert et al., 2007), and pretreatment with HDACis potentiates the effect of ionizing radiation on ATRT cells as measured by a colony-formation assay (Blattmann et al., 2012; Knipstein et al., 2012). SAHA shows synergism with doxorubicin and the cyclinD1 inhibitor fenretinide in inhibiting proliferation of rhabdoid cells (Kerl et al., 2013). Objective ATRT tumor regressions accompanied by increases in histone acetylation were observed in mice after treatment with the natural tetrapeptide HDACi depsipeptide (Graham et al., 2006). The HDACi FK228 (depsipeptide) induces autophagy in malignant ATRT cells by inducing apoptosis inducing factor (AIF) translocation to the nucleus (Watanabe et al., 2009). The cell cycle inhibitor CDKN1C, a tumor suppressor in ATRT, is activated by HDACis (Algar et al., 2009). SAHA combined with fractionated irradiation significantly reduces tumor growth in rhabdoid xenografts (Thiemann et al., 2012). A recent study showed that the epigenetic modulating compound domatinostat (4SC-202), which inhibits both class I HDACs and lysine demethylase (LSD1), displays cytotoxic and cytostatic actions in 2D and 3D ATRT scaffold cell culture models and reduces expression of stemness genes (Hoffman et al., 2020).

THE ROLE OF MODULATING STEMNESS AND DIFFERENTIATION

As discussed above, abnormal epigenetic programming in pediatric cancers may lock tumor cells in a stem cell-like, poorly differentiated state (Lawlor and Thiele, 2012; Marshall et al., 2014). Pediatric brain tumors often display upregulation of genes known as markers of neural stem cells, including CD133, Nestin, and Musashi, and deregulation of other genes that regulate stemness is frequently found (Bahmad and Poppiti, 2020).

HDACis may act partially by restoring expression of prodifferentiation genes, thus influencing tumor cell phenotype toward a less malignant state. In fact, NaB increases the mRNA expression of the neuronal differentiation marker Gria2 in D283 and Daoy cells (Nør et al., 2013). The HDACi panobinostat suppresses leptomeningeal seeding (a strong negative prognostic factor) and prolongs survival in an animal model of MB, while also inducing formation of neurophil-like processes and promoting expression of synaptophysin and NeuroD1, suggesting neuronal differentiation (Phi et al., 2017). Corin promoted change to a more differentiated phenotype in experimental DIPG (Anastas et al., 2019). Treatment with low doses of HDACis can induce terminal differentiation of rhabdoid cells and reduce their ability to self-renew (Muscat et al., 2016).

Given the proposed role of cancer stem cells (CSCs) in the progression, recurrence, and metastasis of brain cancers, studies have also investigated whether HDACis can reduce stemness in MB. Treatment with NaB reduces the formation of MB neurospheres, a model of enriching putative cancer stem cells in culture (Nør et al., 2013). Analyses of MB tumor samples from patients reveals expression of the stemness markers BMI1 and CD133 in all MB molecular subgroups, and NaB is able to reduce BMI1 and CD133 expression in cultured MB cells (Jaeger et al., 2020). In the DKEF-EPIINS model of EPN, SAHA induces neuronal differentiation associated with loss of stemness (Milde et al., 2011). As noted above, HDACi effects in H3K27M DIPG cells involve a decrease in stemness gene expression (Meel et al., 2020). These findings support the view that HDACis should be further investigated as prodifferentiating and stemness modulating agents in pediatric brain tumors. A summary of studies examining the effects of pharmacological inhibition of HDACs in the tumor types reviewed here is presented in Table 1.

CLINICAL TRIALS OF HDACIS IN PEDIATRIC BRAIN TUMORS

A phase-I/II dose-escalation clinical trial of SAHA in pediatric patients with recurrent solid tumors including brain tumors has been reported (Witt et al., 2012). Another phase I trial and pharmacokinetic study of SAHA in children with solid
| Tumor type | Model | HDACis used | Main findings | References |
|------------|-------|-------------|---------------|------------|
| MB         | Daoy and D283 Med, in vitro | MS-275, VPA | Reduced cell proliferation | Jaboin et al., 2002 |
| MB         | Daoy and D283 Med, in vitro | VPA | Reduced cell growth and survival, cell cycle arrest; induction of apoptosis, senescence, and neuronal and glial differentiation; hyperacetylation of histones H3 and H4, activation of p21, and suppression of TP53, CDK4, and c-MYC | Li et al., 2005 |
| MB         | Daoy and D283 Med, subcutaneous (s.c.) xenografts in severe combined immunodeficient mice | VPA, daily systemic injections for 28 days | Reduced tumor growth in vivo | Sonnemann et al., 2006, 2012 |
| MB         | Daoy and UW228-2, in vitro | SAHA, NaB, and TSA | Impairment of mitochondrial membrane potential, activation of caspase-9, -8, and -3, apoptotic cell death; enhancement of cytotoxicity induced by ionizing radiation (IR), etoposide, and TRAIL | Kumar et al., 2007 |
| MB         | Daoy and UW228-2, in vitro | SAHA and TSA | Enhancement of IR-induced cytotoxicity and cell cycle arrest | Häcker et al., 2009 |
| MB         | D458 and primary MB cultures in vitro, chorioallantoic membrane model using D458 cells | MS-275, VPA, and SAHA | Cooperation with cytotoxic chemotherapeutics to induce loss of mitochondrial membrane potential, cytochrome c release, and caspase-dependent apoptosis and reduce cell survival and tumor growth | Häcker et al., 2009 |
| MB         | D341 Med, Daoy, MHH–PNET–5, and UW228–2, in vitro | MS–275, SAHA, TSA, M344, M360, D85, SW55, SW187, and VPA | Reduced cell proliferation, hyperacetylation of H4, reactivation of genes including CASP8, induction of apoptosis | Furchert et al., 2007 |
| MB         | HD-MB03, in vitro | Helmithosporium carbonum (HC)-toxin, SAHA, and panobinostat siRNA-mediated knockdown of HDAC2, HDACis MAZ1863, MAZ1866, SAHA, and MS-275 | Induction of cell death, sensitization to radiation-induced cell death | Milde et al., 2012 |
| MB         | MED8A, UW228-2, ONS76, Daoy, HD-MB03, and D458, in vitro | | Reduced metabolic activity, cell number, and viability; increased sensitivity to HDACi in MYC-amplified cells; increased H4 acetylation and cell death after HDAC2 knockdown; in vitro simulation of clinical pharmacokinetics showed time-dependent on-target activity correlated with binding kinetics of HDACis | Ecker et al., 2015 |
| MB         | D283 Med, in vitro | TSA | Upregulation of Dickkopf-1 (DKK1), a Wnt antagonist | Vibhakar et al., 2007 |
| MB         | ONS-76, in vitro | TSA | Inhibition of telomerase activity, increased expression of p53 and p21, and reduced cyclin-D levels; upregulation of Bax and cytochrome c correlates with TSA-induced apoptosis | Khaw et al., 2007 |
| MB         | HEK293T, in vitro | TSA, NaB, and VPA | Inhibition of ZNF521 cooperation with GLI1 and GLI2 in the transcriptional activation of GLI-responsive promoters | Scicchitano et al., 2019 |
| MB         | Primary culture of CGP cells from Smo/Smo mice, in vitro | TSA and tubastatin | Impairment of Shh-induced CYP proliferation and improvement of aberrant CYP proliferation | Lee et al., 2013 |
| MB         | NIH3T3–12Gli, in vitro | NL-103, SAHA | Decreased resistance to vismodegib, inhibition of the Shh pathway | Zhao et al., 2014 |
| MB         | NIH3T3, Hek293A, ShhL2, and C3H10T1/2, in vitro | TSA, ACY-1215, CAY-10603, tubacin | Inhibition of Hh signaling and expression of genes encoding for components of the Hh pathway | Dhanyamraju et al., 2015 |

(Continued)
| Tumor type | Model | HDACis used | Main findings | References |
|------------|-------|-------------|---------------|------------|
| MB | S.c. injection of primary MB99-1 cells from SmoA1 MB E1270 into C57BL/6J mice | S.c. administration of ACY-1215 (50 mg/kg on days 0, 1, 2, 3, 4, 7, 8, 9, 10, and 11 after tumors were palpable) | Reduced tumor growth | Dhanyamraju et al., 2015 |
| MB | Cre-dependent in vitro system for SHH-driven MB based on cultured primary cerebellar granule neuron precursors from SmoM2FF+ and CrebbpFF/FsmoM2FF+ mice | S.c. administration of ACY-1215 (50 mg/kg on days 0, 1, 2, 3, 4, 7, 8, 9, 10, and 11 after tumors were palpable) | Preferential reduction in cell proliferation and tumor growth in SHH-driven MB harboring a CREBBP mutation | Hellwig et al., 2019 |
| MB | Cre-dependent in vitro system for SHH-driven MB based on cultured primary cerebellar granule neuron precursors from SmoM2FF+ and CrebbpFF/FsmoM2FF+ mice | Intraperitoneal (i.p.) administration of TSA (0.5 µg/g, once daily) | Preferential reduction of tumor growth in SHH-driven MB harboring a CREBBP mutation | Hellwig et al., 2019 |
| MB | MB Cre-dependent in vitro system for SHH-driven MB based on cultured primary cerebellar granule neuron precursors from SmoM2FF+ and CrebbpFF/FsmoM2FF+ mice | JNJ-26481585 (quisinostat), DLS-3, MERCK 60, WT 161, OJl-1, and pantacostat | Inhibitor-specific reduction of cell viability, including SMO-resistant SHH cells, and inhibition of the SHH pathway | Pak et al., 2019 |
| MB | S.c. xenografts into the flank of nude mice; and endogenously arising intracranial SHH MB model in Atoh1-cre::SmoM2Fl/+ mice | Systemic administration of JNJ-26481585 (8 mg/kg) daily, starting at postnatal day P20 | Survival benefit, reduction in expression of SHH target genes Gli1 and Ptc1, good pharmacokinetic profile | Pak et al., 2019 |
| MB | MBA SMB21 (SHH-dependent murine MB cell line) and its mutant derivatives, in vitro | JNJ-26481585 or dacinostat | Reduced cell viability, apoptosis, and Akt phosphorylation; G2/M cell cycle arrest; increased histone H3 and H4 acetylation | Zhang et al., 2019 |
| MB | D458 and primary cultures, in vitro | MS-275, VPA, SAHA | Increased histone H3 and Ku70 acetylation; MS-275 pretreatment-induced enhancement of apoptosis triggered by doxorubicin, etoposide, cisplatin, and topotecan | Häcker et al., 2011 |
| MB | Chorioallantoic membrane model using D458 cells | MS-275 | Increased efficacy in inhibiting tumor growth when combined with doxorubicin | Häcker et al., 2011 |
| MB | Daoy and D283 Med, in vitro | NaB | Increased cell death and expression of the neuronal marker Gria2; reduced neurosphere formation; potentiation of cytotoxic effect of etoposide | Nör et al., 2013 |
| MB | D283 Med, in vitro | SAHA | Enhancement of RA-mediated BMP-2 transcription; induction of apoptosis-mediated cell death potentiated by combination with RA | Spiller et al., 2008 |
| MB | s.c. D283 xenografts injected into the flank of nude mice; intracranial MB in ND2:SmoA1 transgenic mice | SAHA mixed into powdered food at a final concentration of 200 mg/kg/day for up to 21 days (nude mice); i.p. injections of SAHA (200 mg/kg) daily for 3 days in ND2:SmoA1 transgenic mice | Reduced tumor growth with oral SAHA combined with RA in nude mice; increased apoptosis in intracranial tumors and lack of dose-limiting hematopoietic toxicity in ND2:SmoA1 mice | Spiller et al., 2008 |
| MB | Daoy and D283 Med, in vitro | TSA, SAHA, parthenolide, mocetinostat, tacedinaline, romidepsin | Reduced oxygen-dependent cell viability, induction of apoptosis, reduced expression of the stem cell marker CD133, reduced tumorsphere survival. Increased cytotoxic and proapoptotic effects when combined with the DNMT inhibitor 5-aza-dC | Yuan et al., 2017 |
| MB | Daoy, in vitro | 4-Phenybutyrate | Reduced cell viability only when combined with gefitinib; potentiation of effects of gefitinib and vandetanib on cell survival | Marino et al., 2011 |
| Tumor type | Model | HDACis used | Main findings | References |
|------------|-------|-------------|---------------|------------|
| MB         | Daoy and ONS76, in vitro | NaB | Reduction in cell viability by HDACis combined with human recombinant BDNF | Nör et al., 2011 |
| MB         | D283 Med, in vitro | NaB | Reduction of cell viability by NaB alone or combined with bombesin receptor antagonists | Jaeger et al., 2016 |
| MB         | Daoy and D283 Med, in vitro | VPA, SAHA | Induction of cell death through activation of the extrinsic pathway when combined with sorafenib | Tang et al., 2012 |
| MB         | Daoy, in vitro | SAHA | Increased histone acetylation, induction of cytotoxicity, synergistic effects when combined with MLN8237 | Muscal et al., 2013a |
| MB         | UW402, UW473, and ONS-76, in vitro | SAHA | Reduced cell proliferation and survival alone or combined with AMG 900 | Geron et al., 2015 |
| MB         | Patient-derived lines including MB002, ICB-984, ICB-1572, ICB-1497, ICB-1299, Med-1712-FH, Med-411-FH, Med-211-FH, RCMB28, RCMB18, RCMB32, DMB006 | SAHA, HNHA, LBH-589, Scriptaid, MS-275, givinostat, PDX 101, LAQ-824, and MGCD0103 | Inhibition of cell survival through a mechanism targeting FOXO1; synergistic effect with PI3K inhibitors | Pei et al., 2016 |
| MB         | In vivo intracranial tumors generated in NOD-SCID IL2R-gamma null (NSG) mice, from cerebellar stem/progenitor cells (Prom1+ cells) infected with Myc-ires-luciferase and DNP53-ires-GFP retroviruses and stereotactically injected into the cerebellum of 6- to 8-week-old mice | LBH-589 (5 mg/kg) given i.p., in 4-day cycles (3 days on, 1 day off) | Reduced phosphorylation of Akt and S6, increased histone acetylation and FOXO1 content, reduced tumor growth, and prolonged survival; cooperation with the PI3K inhibitor BKM-120 | Pei et al., 2016 |
| MB         | Daoy and D283 Med, in vitro | NaB | Reductions in cell viability and expression of BMI1 and CD133; increased acetylation; anti-proliferative effect potentiated by combination with the MAPK/ERK inhibitor U0126 | Jaeger et al., 2020 |
| MB         | UW228, UW426, MED8A, in vitro | Panobinostat | Reduced cell viability, migration, and adhesion, cell cycle arrest, induction of apoptosis, and neuronal differentiation | Phi et al., 2017 |
| MB         | Orthotopic injection of UW426-effLuc cells in nude mice | Systemic administration of panobinostat (10 mg/kg) every 5 days for 2 weeks | Reduction of tumor growth and leptomeningeal seeding, prolonged survival | Phi et al., 2017 |
| MB         | Daoy and D283 Med, in vitro | FTY720 | Reduced cell viability and survival, increased H3 acetylation | Perla et al., 2020 |
| EPN        | DKFZ-EP1NS, in vitro | SAHA, panobinostat, MS-275, and VPA | Reduced metabolic activity and neurosphere formation capability; induction of neuronal differentiation; loss of stemness; G0–G1 cell cycle arrest | Milde et al., 2011 |
| DIPG       | SU, NEM, JHH, Li, VU, JHH-DIPG-1, SF7761, and primary cultures, in vitro | Panobinostat and SAHA | Decreased cell viability, increased H3 acetylation and HSK27-trimethylation, normalization of K27M gene expression signature, and decrease in MYC gene signature; synergism with GSK-J4 | Grasso et al., 2015 |
| DIPG       | DIPG orthotopic xenograft mouse model, using cells from SU-DIPG-V-luc neurospheres and NOD-SCID-IL2 gamma chain-deficient mice | Panobinostat infused into the pons or given via i.p. injections | Prolonged survival | Grasso et al., 2015 |
| DIPG       | HSJD-DIPG-007 | Panobinostat | Reduced cell survival | Hennika et al., 2017 |
| DIPG       | Autochthonous PDGF-B-H3.3-K27M;p53-deficient BSG genetically engineered mice and DIPG orthotopic xenograft mouse model | I.p. administration of panobinostat (10 to 20 mg/kg), once daily for three to five days | Drug delivery to the brain after systemic administration, reduced tumor cell proliferation, increased H3 acetylation | Hennika et al., 2017 |

(Continued)
**TABLE 1** | Continued

| Tumor type | Model | HDACis used | Main findings | References |
|------------|-------|-------------|---------------|------------|
| DIPG       | DIPG XIII; H3.3 K27M and DIPG XIX; H3.3 K27M primary cells; in vitro | Panobinostat | Reduced cell viability; increased expression of death receptors 4 and 5; cytotoxicity potentiated by combination with hAT-MSC-STRAIL | Choi et al., 2019 |
| DIPG       | VUMC-DIPG-A, VUMC-DIPG-08, VUMC-DIPG-10, SU-DIPG-IV, SU-DIPG-IX, SU-DIPG-XIII, SU-DIPG-XVI, SU-pcGBM-2, HSJD-DIPG-07, HSJD-DIPG-09, HSJD-DIPG-12, JHH DIPG-01, SF7761, SF862826, and mouse cell lines from murine primary tumors, in vitro | Panobinostat | Reduced cell viability and migration; reversal of mesenchymal transition; sensitization to radiation; synergism with the AXL inhibitor BGB324 | Meel et al., 2020 |
| DIPG       | Orthotopic xenografts of HSJD-DIPG-07 Fluc cells in nude mice | Panobinostat (10 mg/kg/day) for four days, or on days 1–5 and 11–13; or a single administration via convection-enhanced delivery (CED, 2 μM) | Prolonged survival when combined with BGB324 | Meel et al., 2020 |
| DIPG       | SU-DIPG-I: H3.1-K27M, SU-DIPG-VI/IXI-III, SU-DIPG-XVII, SU-DIPG-XV, JHH-DIPG-01, SF7761: H3.3-K27M, SU-DIPG-XIII, and VUMC-DIPG-10, in vitro | Panobinostat | Synergistic effects with the bromodomain inhibitor JQ1 and the CDK7 inhibitor THZ1 in reducing cell viability and proliferation and inducing apoptosis; changes in expression of genes related to central nervous system development and synaptic organization and structure | Nagaraja et al., 2017 |
| DIPG       | SF7761, SF8628, and DUB-D003, in vitro | VPA | Reduced cell survival, increased histone H3 acetylation and apoptosis, potentiation of carboplatin cytotoxicity | Killick-Cole et al., 2017 |
| DIPG       | BT869, SF8628, and SF10693 | CUDC-907 | Cytotoxicity with synergism with radiotherapy for CUVC-907; cell cycle arrest, increased DNA damage and reduced DNA repair; inhibition of NFκB and FOXM1 expression and transcriptional activity | Pal et al., 2018 |
| DIPG       | Orthotopic injection of SF8628 cells in nude mice | CUVC-907 (100 mg/kg), orally for 10 days | Increased survival with CUVC-907, with potentiation when combined with radiotherapy | Pal et al., 2018 |
| DIPG       | SU-DIPGVI, SU-DIPGXIII, BT869, BT245, and HSJD-DIPG007 | Panobinostat, entinostat, and Corin | Reduced cell viability, global changes in histone and chromatin modifications and gene expression, cell cycle arrest, induction of differentiation | Anastas et al., 2019 |
| DIPG       | HSJD-DIPG007 and SU-DIPGXIII orthotopic xenografts in nude mice | Corin (0.03 mg) given via CED | Reduced tumor growth, increased H3K27ac and H3K27me3 | Anastas et al., 2019 |
| ATRT       | G401, in vitro | MS-275 | Reduced DNA synthesis and viability, increase in G1, induction of p21 | Jaboin et al., 2002 |
| ATRT       | BT 12, BT 16, 7.92, and G401, in vitro | MS-275, SAHA, TSA, VPA, M344, M380, D85, SW65, SW187 | Reduced cell viability, increased H3 and H4 acetylation, apoptosis induction | Fuchert et al., 2007 |
| ATRT       | KHOS-2405 and A-204, in vitro | SAHA | Reduced cell viability, increased γH2AX expression | Blattmann et al., 2012 |
| ATRT       | BT-12, BT-16, and UPN737 | SAHA, TSA, and SNDCX-275 | Reduced proliferation, increased p21^Waf1,Cip1^ content, induction of apoptosis, potentiation of radiation-induced inhibitor effects on cell survival | Knipstein et al., 2012 |
| ATRT       | BT-12, BT-16, G401, and A-204 | SAHA, TSA, and M344 | Induction of apoptosis, G2 arrest, expression of RB-, MYC-, and pluripotency-associated genes, synergistic cell growth inhibition and apoptosis induction when combined with ferretinide or chemotherapy | Kerl et al., 2013 |
tumors indicated that SAHA was well-tolerated at a dose of 230 mg/m²/d, with a small dose reduction required when SAHA was combined with RA (Fouladi et al., 2010). Another phase-I consortium clinical study recommended a dose and schedule of vorinostat at 230 mg/m²/day PO on days 1-5 and 8-12 in combination with the proteasome inhibitor bortezomib at 1.3 mg/m²/day i.v. on days 1, 4, 8, and 11 of a 21-day cycle, for future phase 2 studies in children with recurrent or refractory solid tumors (Muscat et al., 2013b). SAHA and a range of other epigenetic therapies have been evaluated in clinical trials of patients with DIPG (Hashizume, 2017). An ongoing multicenter, multiarm phase II and III trial investigates the effects of conventional chemotherapy with or without combination with an HDACi in patients with EPN (Merchant, 2017).

CONCLUSION

Some HDACis have already been approved by the United States Food and Drug Administration (FDA) for the treatment of other cancer types (i.e., SAHA and romidepsin for the treatment of cutaneous T-cell lymphoma and belinostat and panobinostat for the treatment of peripheral T-cell lymphoma and multiple myeloma, respectively). Given the increasingly promising role of drug repurposing or repositioning in the identification of potential novel therapeutic strategies for pediatric brain tumors (Bahmad et al., 2020), those agents could be tested in clinical trials of patients with these cancer types. VPA is well tolerated in patients with childhood brain cancers, including heavily pretreated pediatric patients with HGG or DIPG (Wolff et al., 2008; Witt et al., 2012), and could also be evaluated for efficacy in clinical trials of pediatric brain tumors. Moreover, fingolimod (FTY720), an immunosuppressant agent currently used clinically in the treatment of multiple sclerosis, displays HDAC-inhibiting properties and has been recently shown to reduce the growth of experimental MB (Garner et al., 2018; Perla et al., 2020). Reduced D283 and Daoy cell viability by fingolimod was accompanied by increases in acetylated histone H3 levels, highlighting a role for histone acetylation (Perla et al., 2020). Reduced tumor growth with reduced cell proliferation and increased apoptosis with drug treatment alone or combined with radiotherapy (Thiemann et al., 2012).

Pharmacogenomic differences among individual patients pose another challenge for the clinical use of HDACis such as panobinostat for brain tumors is poor permeability across the blood–brain barrier (BBB) after oral administration (Rodgers et al., 2020). Novel formulations and drug administration techniques such as convection-enhanced delivery (CED) are emerging strategies to bypass the BBB, one example being MTC110, a water-soluble formulation of panobinostat (Singleton et al., 2018). Pharmacogenomic differences among individual patients pose another challenge for the clinical use of HDACis. Polymorphic enzymes and drug transporters are involved in metabolizing and transporting HDACIs, making genotype-specific dose a strategy to reduce the risk of toxicity and avoid suboptimal treatment (Goey et al., 2016). Taken together, the evidence reviewed here strongly provides support for further clinical testing of HDACIs as part of the pharmacological treatment available to pediatric brain cancer patients, particularly those with MB or DIPG, tumor types for which there is a larger body of experimental evidence. As the field of therapeutic use of HDACIs for the treatment of brain cancer evolves, one can expect the development and testing of more selective HDACIs that will target specific HDACs and alter the acetylation status of a relatively small number of substrates, potentially reducing side effects associated with less selective HDACIs.

### Table 1

| Tumor type | Model | HDACis used | Main findings | References |
|------------|-------|-------------|---------------|------------|
| ATRT | S.c. xenografts of primary tumors in scid mice | Depsipeptide (4.4 mg/kg) given intravenously (i.v.) every 7 days × 3 with a second cycle of treatment starting on day 21 | Reduced tumor growth, increased histone acetylation, p21 and p53 induction, cleavage of PARP | Graham et al., 2006 |
| ATRT | G401, STM91-01, SJSC, and BT-16 | Romidepsin | Increased CDKN1C mRNA expression and histone acetylation at the CDKN1C promoter, changes in allelic expression of CDKN1C | Algar et al., 2009 |
| ATRT | A-204 s.c. xenografts in nude mice | SAHA (100 mg/kg) injected i.p. once daily for 8 consecutive days or for 15 days within three weeks | Reduced tumor growth with reduced cell proliferation and increased apoptosis with drug treatment alone or combined with radiotherapy | Thiemann et al., 2012 |
| ATRT | CHLA-06-ATRT and CHLA-05-ATRT, in vitro and spheroid and 3D Scaffold models | 4SC-202 | Cytotoxicity, reduced stem cell marker expression, changes in gene networks | Hoffman et al., 2020 |
| ATRT | G401, SJSC, STM91-01 in vitro | LBH589 | Reduced cell viability and self-renewal, induction of senescence, increased H3 and H4 acetylation | Muscat et al., 2016 |
| ATRT | S.c. xenografts of G401 or SJSC in nude mice | Daily i.p. injections of LBH589 (5 mg/kg) | Reduced tumor growth, increased differentiation | Muscat et al., 2016 |

See main text for abbreviation definitions and further details.
AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

FUNDING

This research was supported by the Children’s Cancer Institute (Instituto do Cancer Infantil, ICI); PRONON/Ministry of Health, Brazil (Grant Number 25000.162.034/2014-21); National Council for Scientific and Technological Development (CNPq; Grant Numbers 409287/2016-4 and 305647/2019-9 to RR); the Rio Grande do Sul State Research Foundation (FAPERGS; Grant Number 17/2551-0001 071-0 to RR); the Coordination for the Improvement of Higher Education Personnel (CAPES); and the Clinical Hospital institutional research fund (FIPE/HCPA). CN is also supported by the William Donald Nash fellowship from the Brain Tumour Foundation of Canada.

REFERENCES

Algar, E. M., Muscat, A., Dagar, V., Rickert, C., Chow, C. W., Biegel, J. A., et al. (2009). Imprinted CDKNIC is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors. PLoS One 4:e4482. doi: 10.1371/journal.pone.0004482
Almeida, V. R., Vieira, I. A., Buendia, M., Brunetto, A. T., Greggian, L. J., Brunetto, A. L., et al. (2017). Combined treatments with a retinoid receptor agonist and epigenetic modulators in human neuroblastoma cells. Mol. Neurobiol. 54, 7610–7619. doi: 10.1007/s12035-016-0250-3
Anastas, J. N., Zee, B. M., Kalin, J. H., Kim, M., Guo, R., Alexandrescu, S., et al. (2019). Re-programing chromatin with a bifunctional LSD1/HDAC inhibitor induces therapeutic differentiation in DIPG. Cancer Cell 36, 528–544.e10.
Atlasi, Y., and Stunnenberg, H. G. (2017). The interplay of epigenomic marks during stem cell differentiation and development. Nat. Rev. Genet. 18, 643–658. doi: 10.1038/nrg.2017.57
Athis, P., Blanquart, C., and Fradin, D. (2019). Epigenetic drugs for cancer and microRNAs: a focus on histone deacetylase inhibitors. Cancers 11:1530. doi: 10.3390/cancers11101530
Azzarelli, R., Simons, B. D., and Philpott, A. (2018). The developmental potential future therapies. Mol. Cancer Ther. 17, 627–636. doi: 10.1158/1535-7163.mct-14-0481
Bacchetti, D., Pomeroy, S. L., Pomeranz Krummel, D. A., and Sengupta, A. (2020). Epigenetics and survivalship in pediatric brain tumor patients. J. Neurooncol. 145:dev162693. doi: 10.1242/dev.162693
Becattini, G., Di Marcotullio, L., Greco, A., Coni, S., Antonucci, L., Infante, P., et al. (2010). Histone deacetylase and Cullin3-REN(kDCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation. Nat. Cell Biol. 12, 132–142. doi: 10.1038/ncl2013
Chen, C. S., Weng, S. C., Tseng, P. H., Lin, H. P., and Chen, C. S. (2005). Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J. Biol. Chem. 280, 38279–38287. doi: 10.1074/jbc.m50373200
Choi, S. A., Lee, C., Kwak, P. A., Park, C. K., Wang, K. C., Phi, J. H., et al. (2019). Histone deacetylase inhibitor panobinostat potentiates the anti-cancer effects of mesenchymal stem cell-based sTRAIL gene therapy against malignant glioma. Cancer Lett. 442, 161–169. doi: 10.1016/j.canlet.2018.10.012
De Smaele, E., Di Marcotullio, L., Moretti, M., Pelloni, M., Occhione, M. A., Infante, P., et al. (2011). Identification and characterization of KCASH2 and KCASH3, 2 novel Cullin3 adaptors suppressing histone deacetylase and Hedgehog activity in medulloblastoma. Neoplasia 13, 374–385.
Dhanayamraj, P. K., Holtz, P. S., Finkenrangel, F., Fendrich, V., and Lauth, M. (2015). Histone deacetylase 6 represents a novel drug target in the oncogenic Hedgehog signaling pathway. Mol. Cancer Ther. 14, 727–739. doi: 10.1158/1535-7163.mct-14-0481
D’Mello, S. R. (2020). Histone deacetylases 1, 2 and 3 in nervous system development. Curr. Opin. Pharmacol. 50, 74–81. doi: 10.1016/j.coph.2019.11.007
Dubuc, A. M., Mack, S., Unterberger, A., Northcott, P. A., and Taylor, M. D. (2012). The epigenetics of brain tumors. Methods Mol. Biol. 863, 139–153. doi: 10.1007/978-1-61779-612-8_8
Ecker, J., Oehme, I., Mazitschek, R., Korshunov, A., Kool, M., Hielscher, T., et al. (2015). Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma. Acta Neurochir. Commun. 3:22.
Erelk, S., Johann, P. D., Finetti, M. A., Drosos, Y., Chou, H. C., Zapatka, M., et al. (2019). Comprehensive analysis of chromatin states in atypical teratoid/rhabdoid tumor identifies diverging roles for SWI/SNF and polycomb in gene regulation. Cancer Cell 35, 95–110.e8.
Falkenberg, K. J., and Johnstone, R. W. (2014). Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat. Rev. Drug Discov. 13, 673–691. doi: 10.1038/nrd4360
Ferretti, E., De Smaele, E., Miele, E., Lannev, P., Po, A., Pelloni, M., et al. (2008). Concerted microRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells. EMBO J. 27, 2616–2627. doi: 10.1038/emboj.2008.172
Fouladi, M., Park, J. R., Stewart, C. F., Gilbertson, R. J., Schaiquevich, P., Sun, J., et al. (2010). Pediatric phase I trial and pharmacokinetic study of vorinostat: A Children’s Oncology Group phase I consortium report. J. Clin. Oncol. 28, 632–6329. doi: 10.1200/jco.2009.25.9119
Fruhwald, M. C., Biegel, J. A., Bourdeaut, F., Roberts, C. W., and Chi, S. N. (2016). Suberoylanilide hydroxamic acid affects regions amplified in tumors. Cell 164, 306–319.e10.
Frunkle, M. C., O’Donis, M. S., Dai, Z., Rush, L. J., Krahe, R., Smiraglia, D. J., et al. (2001). Aberrant hypermethylation of the major breakpoint cluster region in 17p11.2 in medulloblastomas but not supratentorial PNETs. Genes Chromosomes Cancer 30, 38–47. doi: 10.1002/1098-2264(2000019999.9999-aid-gcc1052-3.0.co;2-s
Funato, K., Major, T., Lewis, P. W., Allis, C. D., and Tabar, V. (2014). Epigenetic embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation. Science 346, 1529–1533. doi: 10.1126/science.1253799

Frontiers in Cell and Developmental Biology | www.frontiersin.org 11 July 2020 | Volume 8 | Article 546

Perla et al.

HDACs in Pediatric Brain Cancers
Fuchter, S. E., Lanvers-Kaminsky, C., Juürgens, H., Jung, M., Loidl, A., and Friwhald, M. C. (2007). Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. *Int. J. Cancer* 120, 1787–1794. doi: 10.1002/ijc.22401

Garg, N., Vijayakumar, T., Bakhshandian, D., Venugopal, C., and Singh, S. K. (2015). MicroRNA regulation of brain tumour initiating cells in central nervous system tumours. *Stem Cells Int.* 2015:147193.

Garner, E. F., Williams, A. P., Stafman, D. L., Aye, J. M., Mroczek-Musulman, E., Moore, B. P., et al. (2018). FTY720 decreases tumorigenesis in group 3 medulloblastoma patient-derived xenografts. *Sci. Rep.* 8:6913.

Geron, L., Barges, K. S., Andrade, A. F., Suazo, V. K., Sciredi, C. A., and Tone, L. G. (2015). Antitumour activity of AMG 900 alone or in combination with histone deacetylase inhibitor SAHa on medulloblastoma cell lines. *Neural. Res.* 37, 703–711. doi: 10.1177/1743132815000000048

Glozak, M. A., Sengupta, N., Zhang, X., and Soto, E. (2005). Acetylation and deacetylation of non-histone proteins. *Gene* 363, 15–23. doi: 10.1016/j.gene.2005.09.010

Goey, A. K., Sissung, T. M., Peer, C. J., and Figg, W. D. (2016). Pharmacogenomics and histone deacetylase inhibitors. *Pharmacogenomics* 17, 1807–1815. doi: 10.2217/pps-2016-0113

Graham, C., Tucker, C., Creech, J., Favours, E., Billups, C. A., Liu, T., Goey, A. K., Sissung, T. M., Peer, C. J., and Figg, W. D. (2016). Pharmacogenomics and histone deacetylase inhibitors. *Cancer* 22, 701–705. doi: 10.1002/jpc.24322

Grau, S. E., Tang, Y., Brawford, N. E., Liu, L., Debily, M. A., et al. (2015). Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. *Nat. Med.* 21, 555–559.

Guido, L. J. (2013). Retinoids induce stem cell differentiation via epigenetic changes. *Semin. Cell Dev. Biol.* 24, 701–705. doi: 10.1016/j.semcdb.2013.08.002

Guerrero Stuckland, A. S., Rasamwanyi, V., Daniels, C., and Taylor, M. D. (2018). Review of molecular classification and treatment implications of pediatric brain tumors. *Curr. Opin. Pediatr.* 30, 3–9. doi: 10.1097/mop.0000000000000562

Hacker, S., Dittrich, A., Mohn, A., Schweitzer, T., Rutkowski, S., Krauss, J., et al. (2009). Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. *Oncogene* 28, 3097–3110. doi: 10.1038/onc.2009.161

Häcker, S., Karl, S., Mader, I., Cristofanon, S., Schweitzer, T., Krauss, J., et al. (2011). Histone deacetylase inhibitors prime medulloblastoma cells for chemotherapy-induced apoptosis by enhancing p53-dependent Bax activation. *Oncogene* 30, 2275–2281. doi: 10.1038/onc.2010.599

Hashizume, R. (2017). Epigenetic targeted therapy for diffuse intrinsic pontine glioma. *Neurol. Med. Chir.* 61, 630–640. doi: 10.1293/neo.67.667

Hashimzadeh, M. G. (2015). Antitumour activity of AMG 900 alone or in combination with histone deacetylase inhibitor SAHa on medulloblastoma cell lines. *Neurol. Res.* 37, 703–711. doi: 10.1177/1743132815000000048

Hassell, K. N. (2019). Histone deacetylases and their inhibitors in cancer therapy: Is transcription the primary target? *Cancer Cell* 4, 13–18.

Jones, D. T., Jäger, N., Kool, M., Zichner, T., Hutter, B., Sultan, M., et al. (2012). Dissecting the genomic complexity underlying medulloblastoma. *Nature* 488, 100–105.

Kerl, K., Ries, D., Unland, R., Borchert, C., Moreno, N., Hasselblatt, M., et al. (2013). The histone deacetylase inhibitor SAHA acts in synergy with fenretinide and doxorubicin to control growth of rhabdoid tumor cells. *BMC Cancer* 13:286. doi: 10.1186/1471-2407-13-286

Khwaj, A. K., Silasudjana, M., Banerjee, B., Suzuki, M., Baskar, R., and Hande, M. P. (2007). Inhibition of telomerase activity and human telomerase reverse transcriptase gene expression by histone deacetylase inhibitor in human brain cancer cells. *Mutat. Res.* 625, 134–144. doi: 10.1016/j.mrfmmm.2007.06.005

Killick-Cole, C. L., Singleton, W. G. B., Bienemann, A. S., Asby, D. J., Wyatt, M. J., Boulter, L. J., et al. (2017). Repurposing the anti-epileptic drug valproate as an adjuvant treatment for diffuse intrinsic pontine glioma. *PLoS One* 12:e0176855. doi: 10.1371/journal.pone.0176855

Kim, K. H., and Roberts, C. W. (2016). Targeting EZH2 in cancer. *Nat. Med.* 22, 128–134. doi: 10.1038/nm.4036

Knipstein, J. A., Birks, D. K., Donson, A. M., Alimova, I., Foreman, N. K., and Vibhakar, R. (2012). Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells. *Neuro Oncol.* 14, 175–183. doi: 10.1093/neuonc/nox208

Kouzarides, T. (2007). Chromatin modifications and their function. *Cell* 128, 693–705. doi: 10.1016/j.cell.2007.02.005

Kumar, K. S., Sonnemann, J., Hong le, T. T., Rurman, C., Adler, F., Maass, M., et al. (2007). Histone deacetylase inhibitors, but not vincristine, cooperate with radiotherapy to induce cell death in medulloblastoma. *Anticancer Res.* 27, 465–470.

Lahm, A., Paolini, C., Pallaoro, M., Nardi, M. C., Jones, P., Neddermann, P., et al. (2007). Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. *Proc. Natl. Acad. Sci. U.S.A.* 104, 17335–17340. doi: 10.1073/pnas.0706487104

Lancaster, C. J. (2012). Epigenetic changes in pediatric solid tumors: promising new targets. *Clin. Cancer Res.* 18, 2768–2779. doi: 10.1158/1078-0432.ccr-11-1921

Lee, R. S., Stewart, C., Carter, S. L., Triagio, L., Cibulskis, K., Sougnez, C., et al. (2012). A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. *J. Clin. Invest.* 122, 2983–2988. doi: 10.1172/jci64400

Lee, S. J., Lindsey, S., Graves, B., Yoo, S., Olson, J. M., Langhans, S. A. (2013). Sonic hedgehog-induced histone deacetylation activation is required for cerebellar granule precursor hyperplasia in medulloblastoma. *PLoS One* 8:e71455. doi: 10.1371/journal.pone.0071455

Leichter, A. L., Sullivan, M. J., Eccles, M. R., and Chatterjee, A. (2017). MicroRNA expression patterns and signalling pathways in the development and progression of childhood solid tumours. *Mol. Cancer* 16:15.

Li, A. M., Dunham, C., Tabori, U., Carret, A. S., McNeely, P. D., Johnston, D., et al. (2015). EZH2 expression is a prognostic factor in childhood intracranial ependymoma. *J. Cancer Therapy* 6, 1912–1922. doi: 10.1158/1535-7163.mct-05-0184
Li, Y., and Seto, E. (2016). HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb. Perspect. Med. doi:10.1101/cshperspect.a026831

Liu, C., and Zong, H. (2012). Developmental origins of brain tumors. Curr. Opin. Neurobiol. 22, 844–849. doi:10.1016/j.conb.2012.04.012

Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., et al. (2016). The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 131, 803–820. doi:10.1007/s00401-016-1545-1

Lue, J. K., Prabhu, S. A., Liu, Y., Gonzalez, Y., Verma, A., Mundi, P. S., et al. (2019). Precision targeting with EZH2 and HDAC inhibitors in epigenetically dysregulated lymphomas. Clin. Cancer Res. 25, 5271–5283. doi:10.1158/1078-0432.ccr-18-3989

Mack, S. C., Hubert, C. G., Miller, T. E., Taylor, M. D., and Rich, J. N. (2016). An epigenetic gateway to brain tumor cell identity. Nat. Neurosci. 19, 10–19. doi:10.1038/nn.4190

Mack, S. C., and Taylor, M. D. (2009). The genetic and epigenetic basis of ependymoma. Childs Nerv. Syst. 25, 1195–1201. doi:10.1007/s00438-009-0928-1

Mack, S. C., Witt, H., Piro, R. M., Gu, L., Zuyderduyn, S., Stütz, A. M., et al. (2014). Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 506, 445–450.

Marino, A. M., Sofiadis, A., Baryawno, N., Johnsen, I. J., Larsson, C., Vukojevic, V., et al. (2011). Enhanced effects by 4-phenylbutyrate combination with RTK inhibitors on proliferation in brain tumor cell models. Biochem. Biophys. Res. Commun. 411, 208–212. doi:10.1016/j.bbrc.2011.06.141

Marshall, G. M., Carter, D. R., Cheung, B. B., Liu, T., Mateos, M. K., Meyerowitz, J. G., et al. (2014). The prenatal origins of cancer. Nat. Rev. Cancer 14, 277–289.

Mee, M. H., de Gooijer, M. C., Metselaar, D. S., Sewing, A. C. P., Zwaan, K., et al. (2012). A novel human high-risk ependymoma stem cell model reveals transcriptional complexes, and pharmacological actionability. Mol. Neurobiol.

Merchant, T. E. (2017). Current clinical challenges in childhood ependymoma: a focused review. J. Clin. Oncol. 35, 2364–2369. doi:10.1200/jco.2017.73.1265

Milazzo, G., Mercatelli, D., Di Muzio, G., Triboli, L., De Rosa, P., Perini, G., et al. (2020). Histone deacetylases (HDACs): evolution, specificity, role in transcriptional complexes, and pharmacological actionability. Genes 11:E556.

Milde, T., Kleber, S., Korshunov, A., Witt, H., Hielscher, T., Koch, P., et al. (2011). A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat. Acta Neuropathol. 122, 637–650. doi:10.1007/s00401-011-0866-3

Milde, T., Lodrini, M., Savelyeva, L., Korshunov, A., Kool, M., Bruecker, L. M., et al. (2012). HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment. J. Neurooncol. 110, 335–348. doi:10.1007/s10639-012-0978-1

Milde, T., Oehme, L., Korshunov, A., Kopp-Schneider, A., Remke, M., Northcott, P., et al. (2010). HDACs and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth. Clin. Cancer Res. 16, 3240–3252. doi:10.1158/1078-0432.CCR-10-0395

Millard, C. J., Watson, P. J., Fairall, L., and Schwabe, J. W. R. (2017). Targeting class HDAC and PI3K antagonists cooperate to inhibit growth of MYC-driven medulloblastoma. Mol. Neurobiol.

Millard, C. J., Watson, P. J., Fairall, L., and Schwabe, J. W. R. (2017). Targeting class HDAC and PI3K inhibition abrogates NFkB- and FOXM1-mediated DNA damage response to radiosensitize pediatric high-grade gliomas. Cancer Res. 78, 4007–4021. doi:10.1158/0008-5472.can-17-3691

Park, P. C., Taylor, M. D., Mainprize, T. G., Becker, L. E., Ho, M., Mura, W. T., et al. (2003). Transcriptional profiling of medulloblastoma in children. J. Neurosurg. 99, 534–541. doi:10.3171/jns.2003.99.5.0354

Parsons, D. W., Li, M., Zhang, X., Jones, S., Leary, R. J., Lin, J. C., et al. (2011). The genetic landscape of the childhood cancer medulloblastoma. Science 331, 435–439.

Pei, Y., Liu, K. W., Wang, J., Garancher, A., Tao, R., Esparza, L. A., et al. (2016). HDAC and PI3K antagonists cooperate to inhibit growth of MYC-driven medulloblastoma. Cancer Cell 29, 311–323. doi:10.1016/j.ccell.2016.02.011

Perla, A. S., Fratini, L., Cardoso, P. S., de Farias, C. B., da Cunha Jaeger, M., Cardoso, P. S., de Farias, C. B., da Cunha Jaeger, M., and Brassesco, M. S. (2019). Abramerrantly expressed microRNAs and their implications in childhood central nervous system tumors. Cancer Metastasis Rev. 38, 813–828. doi:10.1007/s10555-019-09820-6

Purification, C. J., Choi, S. A., Kwak, P. A., Lee, J. Y., Wang, K. C., Hwang, D. W., et al. (2017). Panobinostat, a histone deacetylase inhibitor, suppresses leptomeningeal seeding in a medulloblastoma animal model. Oncotarget 8, 56747–56757. doi:10.18632/oncotarget.18132

Ramsawhok, A., Lewis, L., Coyle, B., and Ruzov, A. (2017). Medulloblastoma and ependymoma cells display increased levels of 5-carboxylxycytosine and elevated TET1 expression. Clin. Epigenetics 9:18.

Ribatti, D., and Tamma, R. (2020). Epigenetic control of tumor angiogenesis. Microcirculation 27:e12602.

Rodgers, L. T., Lester McCully, C. M., Odabas, A., Cruz, R., Peer, C. J., Figg, W. D., et al. (2020). Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma. Cancer Chemother. Pharmacol. 85, 827–830. doi:10.1007/s00280-019-04021-y

Sanaei, M., and Kavoosi, F. (2019). Histone deacetylase and histone deacetylase inhibitors: molecular mechanisms of action in various cancers. Adv. Biomed. Res. 8:63. doi:10.4103/abrir.abrir_142_19
Schwartzentruber, J., Korshubin, A., Liu, X. Y., Jones, D. T., Pfaff, E., Jacob, K., et al. (2012). Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. *Nature* 482, 226–231.

Scicchitano, S., Giordano, M., Lucchino, V., Montalcini, Y., Chiarella, E., Aloisio, A., et al. (2019). The stem cell-associated transcription co-factor, ZNF521, interacts with GLI1 and GLI2 and enhances the activity of the Sonic hedgehog pathway. *Cell Death Dis.* 10:715.

Shim, K. W., Xi, G., Farnell, B. M., Kim, D. S., Tsurubuchi, T., Tomita, T., et al. (2015). Epigenetic modification after inhibition of IGF-1R signaling in human central nervous system atypical teratoid rhabdoid tumor (AT/RT). *Childs Nerv. Syst.* 29, 1245–1251. doi: 10.1007/s00381-013-2087-7

Sin-Chan, P., and Huang, A. (2014). DNMTs as potential therapeutic targets in hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor. *Exp. Neurol.* 252, 80–90. doi: 10.1016/j.expneurol.2012.11.014

Wang, X., Lee, R. S., Alver, B. H., Haswell, J. R., Wang, S., Mieczkowski, J., et al. (2017). SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation. *Nat. Genet.* 49, 289–295. doi: 10.1038/ng.3746

Watanabe, M., Adachi, S., Matsubara, H., Imai, T., Yui, Y., Mizushima, Y., et al. (2009). Induction of autophagy in malignant rhabdoid tumor cells by the histone deacetylase inhibitor FK228 through ALF translocation. *Int. J. Cancer* 124, 55–67. doi: 10.1002/ijc.23897

Witt, O., Milde, T., Deubzer, H. E., Oehme, L., Witt, B., Kulozik, A., et al. (2012). Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia. *Klin. Padiatr.* 224, 398–403. doi: 10.1055/s-0032-1323692

Visvader, J. E. (2011). Cells of origin in cancer. *Nature* 469, 314–322.

Waha, A., Koch, A., Hartmann, W., Mack, H., Schramm, J., Sörensen, N., et al. (2004). Analysis of HIC-1 methylation and transcription in human ependymomas. *Int. J. Cancer* 110, 542–549. doi: 10.1002/ijc.20519

Wang, J., and Wechsler-Reya, R. J. (2014). The role of stem cell pathways in the genesis of medulloblastoma. *Exp. Neurol.* 260, 69–73. doi: 10.1016/j.expneurol.2012.11.014

Visvader, J. E. (2011). Cells of origin in cancer. *Nature* 469, 314–322.

Waha, A., Koch, A., Hartmann, W., Mack, H., Schramm, J., Sörensen, N., et al. (2004). Analysis of HIC-1 methylation and transcription in human ependymomas. *Int. J. Cancer* 110, 542–549. doi: 10.1002/ijc.20519

Wang, J., and Wechsler-Reya, R. J. (2014). The role of stem cell pathways in the genesis of medulloblastoma. *Exp. Neurol.* 260, 69–73. doi: 10.1016/j.expneurol.2012.11.014

Wang, X., Lee, R. S., Alver, B. H., Haswell, J. R., Wang, S., Mieczkowski, J., et al. (2017). SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation. *Nat. Genet.* 49, 289–295. doi: 10.1038/ng.3746

Watanabe, M., Adachi, S., Matsubara, H., Imai, T., Yui, Y., Mizushima, Y., et al. (2009). Induction of autophagy in malignant rhabdoid tumor cells by the histone deacetylase inhibitor FK228 through ALF translocation. *Int. J. Cancer* 124, 55–67. doi: 10.1002/ijc.23897

Witt, O., Milde, T., Deubzer, H. E., Oehme, L., Witt, B., Kulozik, A., et al. (2012). Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia. *Klin. Padiatr.* 224, 398–403. doi: 10.1055/s-0032-1323692

Wolff, J. E., Kramm, C., Kortmann, R. D., Pietsch, T., Rutkowski, S., Jorch, N., et al. (2008). Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. *J. Neurooncol.* 90, 309–314. doi: 10.1007/s11060-008-9662-x

Wu, G., Broniscer, A., McEachron, T. A., Lu, C., Paugh, B. S., Becksfort, J., et al. (2012). Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. *Nat. Genet.* 44, 251–253. doi: 10.1038/ng.1102

Wu, G., Diaz, A. K., Paugh, B. S., Rankin, S. L., Lu, B., Li, Y., et al. (2014). The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. *Nat. Genet.* 46, 444–450. doi: 10.1038/ng.2938

Yuan, J., Llamas Luceño, N., Sander, B., and Golas, M. M. (2017). Synergistic anticancer effects of epigenetic drugs on medulloblastoma cells. *Cell Oncol.* 40, 263–279. doi: 10.1007/s13402-017-0319-7

Zhang, M., Zhu, D., Zhang, Z., Kaluz, S., Yu, B., Devi, N. S., et al. (2020). EZH2 targeting reduces medulloblastoma growth through epigenetic reactivation of the BAI1/p53 tumor suppressor pathway. *Oncogene* 39, 1041–1048. doi: 10.1038/s41388-019-1036-7

Zheng, S., Gong, Z., Oladimeji, P. O., Currier, D. G., Deng, Q., Liu, M., et al. (2019). A high-throughput screening identifies histone deacetylase inhibitors as therapeutic agents against medulloblastoma. *Exp. Hematol.* 83:10.

Zhao, J., Quan, H., Xie, C., and Lou, L. (2014). NL-103, a novel dual-targeted inhibitor of histone deacetylases and hedgehog pathway, effectively overcomes vismodegib resistance conferred by Smo mutations. *Pharmacol. Res. Perspect.* 2:e00043. doi: 10.1016/j.prp2.43